Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
| Brand name | PRAZOSIN HYDROCHLORIDE |
| Generic name | PRAZOSIN HYDROCHLORIDE |
| Active ingredient(s) | PRAZOSIN HYDROCHLORIDE |
| Distributed by / for | TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules |
| NDC | 0093-4068-01 |
| Full product label | Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4068-01, b) 1000 Capsules, NDC 0093-4068-10 |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Distribution | U.S. Nationwide |
| Quantity | 291,512 bottles |
| Recall initiated | 2025-10-07 |
| Report date | 2025-11-05 |
| Recall completed | — |
| Recall number | D-0105-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗